New peer-reviewed publication

AI SummaryClose X

ImmuPharma PLC announced the publication of new peer-reviewed research in Pharmacological Research detailing the activity of P140 in a preclinical model of metabolic dysfunction-associated steatohepatitis (MASH). The study demonstrated that P140 treatment reduced steatohepatitis and liver fibrosis in mice, improving several disease-related parameters by selectively modifying dysregulated lysosomal and autophagy-associated markers. This research provides further evidence of P140's biological activity beyond its original lupus indication and supports its continued investigation in diseases characterized by cellular homeostasis and autophagy disruption.

Disclaimer*

Companies

Immupharma (IMM)
UK 100

Latest directors dealings